Stem Cell Therapy Market
授權報價
| Single User | $4,799 USD |
| Multi User | $7,999 USD |
| Enterprise / Global Site Licence | $17,999 USD |
完整報告名稱與涵蓋範圍
Stem Cell Therapy Market by Source of Stem Cell, Origin of Stem Cell, Type of Stem Cell, Lineage of Stem Cell, Route of Administration, Therapeutic Area, End Users and Geographical Regions – Trends and Global Forecast Till 2035
報告摘要
STEM CELL THERAPY MARKET: OVERVIEW
As per Roots Analysis, the global stem cell therapy market is estimated to grow from USD 321 million in the current year to USD 1,290 million by 2035, registering a CAGR of 16.7% across the forecast period.
Stem Cell Therapy Market: Growth and Trends
Stem cell therapies represent one of the most promising frontiers within regenerative medicine. These therapies harness the innate ability of stem cells to replace damaged tissue, restore organ function and address the root cause of disease, rather than merely managing its symptoms. As per the recent data, more than 50% of the global population is currently living with some form of chronic illness, a burden that has intensified the search for durable, disease-modifying treatment alternatives. Since the first bone marrow transplant in the 1950s, advances in cell biology and regenerative medicine have accelerated the development of stem cell-based therapies. These interventions are designed to address unmet needs across a broad range of disease indications.
To date, close to 25 stem cell therapies have secured regulatory approval from the USFDA. Some notable examples include EYE-01M, Alofisel®, MACI, Stempeucel® and Strimvelis®. Additionally, more than 280 stem cell-based product candidates are being evaluated across various stages of development by over 120 industry players worldwide. Their progress is supported by an active clinical pipeline comprising more than 540 ongoing and completed trials involving over 52,000 patients globally. The applicability of stem cell therapies now spans more than 25 distinct therapeutic areas, with cardiovascular, neurological, musculoskeletal and autoimmune / inflammatory disorders emerging as the primary areas of clinical and commercial focus.
The market has also benefited from heightened regulatory support for regenerative therapies. For instance, the USFDA released guidance in September 2025 to promote adaptive trial designs and accelerated approval pathways for cell-based treatments. Continued capital inflows, an expanding contract manufacturing ecosystem, and positive late-stage clinical results across neurodegenerative, cardiovascular, and autoimmune indications are strengthening confidence in the long-term commercial potential of stem cell therapies.
Growth Drivers: Factors Fueling Market Expansion
Market growth is being propelled by the rising global burden of chronic and degenerative disorders for which conventional pharmacological interventions offer largely palliative, rather than curative, benefit. The consequent unmet need is driving sustained investment into cell-based regenerative platforms capable of restoring tissue and organ function. This momentum is further reinforced by an increasingly favorable regulatory climate, with agencies across North America, Europe and Japan introducing expedited review pathways and adaptive trial frameworks tailored specifically to advanced and cell-based therapies.
Additional impetus is being provided by the growing maturity of the stem cell manufacturing ecosystem. Further, the availability of specialized contract development and manufacturing organizations (CDMOs) is enabling smaller developers to scale production without the burden of establishing proprietary manufacturing infrastructure. Government and philanthropic funding from organizations such as the National Institutes of Health (NIH) and the California Institute for Regenerative Medicine continues to drive early-stage research. Meanwhile, growing venture capital investment is helping advance promising academic discoveries into clinical-stage assets.
Market Challenges: Critical Barriers Hindering Progress
Despite the encouraging outlook, the stem cell therapy market continues to contend with several structural challenges. A major challenge is the technical and operational complexity of developing and manufacturing stem cell-based products. These therapies require specialized infrastructure, stringent quality control, and highly skilled personnel, making development difficult for smaller companies and slowing pipeline advancement.
Reimbursement uncertainty, the high cost of therapy development and administration, and evolving regulatory expectations across geographies further complicate market entry and commercialization strategies. Additionally, the field's historical association with ethical considerations around embryonic stem cell sourcing continues to influence the pace of adoption in certain regions, reinforcing the relative commercial preference for adult stem cell-derived products. Collectively, these factors underscore the need for well-defined manufacturing partnerships, robust regulatory strategy and differentiated clinical positioning among market participants.
Stem Cell Therapy Market: Key Insights
The report delves into the current state of the stem cell therapy market and identifies potential growth opportunities for the market players. Some key findings include:
• Driven by the rising burden of chronic and degenerative disorders and the limitations of conventional treatment paradigms, more than 120 industry and non-industry players are currently engaged in the development of stem cell-based therapies, evaluating over 280 product candidates across various stages of development.
• Close to 25 stem cell therapies have received regulatory approval to date; notable examples include EYE-01M, Alofisel®, MACI, Stempeucel® and Strimvelis®, reflecting a maturing translational pathway from bench to bedside.
• Mesenchymal stem cells represent the most extensively investigated cell type within the current pipeline, owing to their favorable immunomodulatory profile, ease of isolation and broad applicability across multiple therapeutic areas.
• Cardiovascular, neurological, musculoskeletal and autoimmune / inflammatory disorders are presently the primary focus areas for stem cell therapy developers, collectively accounting for a majority of pipeline activity.
• More than 540 clinical trials evaluating novel stem cell therapies, enrolling over 52,000 patients, have been registered to date; a majority of these studies are being conducted at centers across the US.
• Over USD 600 million has been awarded in the form of grants by government and philanthropic bodies to research institutes engaged in stem cell therapy-related projects, underscoring sustained public sector commitment to this field.
• More than 80 industry and non-industry players, based across different regions, presently offer contract development and manufacturing services catering to the specific needs of stem cell therapy developers.
• Products based on bone marrow-derived adult stem cells are anticipated to continue dominating the market over the mid-to-long term, while adoption of therapies administered via novel and minimally invasive routes is expected to rise steadily.
• Given the robust pipeline of novel stem cell therapy candidates, sustained R&D investment and improving regulatory clarity, the stem cell therapy market is well-positioned to witness sustained double-digit growth through 2035.
Stem Cell Therapy Market Segments
The market sizing and opportunity analysis has been segmented across the following parameters:
By Source of Stem Cell
• Allogeneic Therapies
• Autologous Therapies
By Origin of Stem Cell
• Adult Stem Cells
• Embryonic Stem Cells
By Type of Stem Cell
• Hematopoietic Stem Cells
• Mesenchymal Stem Cells
• Progenitor Cells
• Others
By Lineage of Stem Cell
• Adipose Tissue Derived Stem Cells
• Bone Marrow Derived Stem Cells
• Cord Blood Derived Stem Cells
By Route of Administration
• Intraarticular
• Intracoronary
• Intramuscular
• Intramyocardial
• Intrathecal
• Intravenous
• Surgical Implantation
• Others
By Therapeutic Area
• Autoimmune / Inflammatory Disorders
• Cardiovascular Disorders
• Metabolic Disorders
• Musculoskeletal Disorders
• Oncological Disorders
• Neurological Disorders
• Ophthalmic Disorders
• Others
By End Users
• Ambulatory Surgery Centers
• Hospitals
• Specialty Clinics
By Geographical Regions
• North America
• Europe
• Asia-Pacific
• Rest of the World
Stem Cell Therapy Market: Key Segments
Allogeneic Therapies Poised to Gain Share of the Market in Future
Based on Roots Analysis market assessment, autologous approaches continue to command a high share of ongoing clinical activity owing to their favorable immunological profile, allogeneic "off-the-shelf", stem cell therapies are gaining momentum on account of their scalability, cost-efficiency and shorter turnaround time to patient administration. This shift is expected to play an important role in shaping commercial strategy among developers seeking to optimize manufacturing economics.
Mesenchymal Stem Cell (MSC)-Based Therapies Lead the Market
Based on the Roots Analysis market report, mesenchymal stem cell (MSC)-based therapies currently hold the highest share as it represents the most active area of pipeline development. This growing pipeline of mesenchymal stem cell-based drugs reflects their well-documented immunomodulatory and regenerative properties. Additionally, relative ease of isolation from multiple tissue sources, and broad applicability across autoimmune, orthopedic and cardiovascular indications.
North America Expected to Retain Market Leadership
North America is projected to remain the largest regional market for stem cell therapies through 2035. This dominance is supported by a well-established regenerative medicine ecosystem, a high concentration of therapy developers and CDMOs, favorable reimbursement dynamics for advanced therapies, and continued grant funding from bodies such as the NIH.
Asia-Pacific to Emerge as a Highest Growing Regional Market
The Asia-Pacific stem cell therapy market is anticipated to register higher CAGR over the forecast period. This growth is driven by an expanding base of domestic developers, increasing clinical trial activity, improving regulatory clarity in key markets such as Japan and South Korea, and rising healthcare investment across the region.
Example Players in Stem Cell Therapy Market
• Anterogen
• Athersys
• CHA Biotech
• Cytopeutics
• Hope Biosciences
• Mesoblast
• Pluristem Therapeutics
• Takeda Pharmaceutical
• TICEBA
Expert Interview and Industry Insights
The opinions and insights presented in this study have been influenced by discussions conducted with multiple industry stakeholders. The research report features detailed transcripts of interviews held with, among others, the following industry representatives:
• Founder and Chief Executive Officer, Seraxis
• Chief Executive Officer, Xcelthera
• Co-Founder and Chief Scientist, Kadimastem
• Director and Chief Operating Officer, Heartseed
• Director and Chairman, Department of Cardiac Surgery, University of Rostock
• President, Bio Elpida
• Professor and American Red Cross Chair in Transfusion Medicine, University of Minnesota
• Manager of Business Development, Waisman Biomanufacturing
• Department Leader, Cell Therapy Innovation and Development, YposKesi
STEM CELL THERAPY MARKET: RESEARCH COVERAGE
• Market Sizing and Opportunity Analysis: An in-depth, top-down analysis of the global stem cell therapy market, covering key segments including source of stem cell, origin of stem cell, type of stem cell, lineage of stem cell, route of administration, therapeutic area, end users and geographical regions.
• Market Introduction: A review of the historical evolution of stem cell research, classification of stem cells (by source, origin and potency), modes of administration, applications and associated development challenges, alongside a summary of regulatory guidelines across North America, Europe and Japan.
• Market Landscape: A comprehensive assessment of the marketed and clinical-stage stem cell therapy pipeline, analyzed by phase of development, source, origin, type, lineage and potency of stem cell, target indication, therapeutic area and route of administration, supported by tree map, heptagon, grid and world map representations of industry activity.
• Company Profiles: In-depth profiles of prominent players engaged in the stem cell therapy domain, featuring information on year of establishment, location of headquarters, company size, product portfolio and recent developments.
• Key Therapeutic Areas: A disease-specific assessment of over 20 target indications spanning autoimmune / inflammatory, cardiovascular, dermatological, metabolic, oncological and neurological disorders, including epidemiology, current treatment options and the corresponding stem cell therapy pipeline.
• Assessment of Relative Competition and Growth: A proprietary 2×2 framework evaluating existing competition and growth opportunity across established and emerging therapeutic areas, within both established and emerging geographies.
• Academic Grants Analysis: An analysis of grants awarded by the National Institutes of Health (NIH) for stem cell therapy-related research, based on year of award, amount awarded, funding mechanism, therapeutic area, and recipient organization, along with a multivariate grant attractiveness analysis.
• Clinical Trial Analysis: An analysis of completed, ongoing and planned clinical trials, based on trial registration year, phase, recruitment status, sponsor / collaborator type, study design, patient enrollment, therapeutic area and geography.
• Stem Cell Manufacturing Landscape and CDMO Evaluation: A review of the contract manufacturing landscape for stem cell therapies, featuring information on industry and non-industry CDMOs (by year of establishment, company size, scale of manufacturing, services offered and location), along with a KPI framework for evaluating prospective manufacturing partners.
• Developers and CMOs: Opportunity Assessment: A gap analysis comparing the clinical and commercial capabilities of therapy developers against the availability of contract manufacturing capacity, across North America, Europe and Asia-Pacific / Rest of the World.
• Key Commercialization Strategies: An assessment of strategies adopted by developers before and after therapy approval, including profiles of key approved stem cell therapies and an evaluation of opportunities and challenges associated with unapproved therapies.
• Market Sizing and Forecast, By Segment and Geography: Historical trends (since 2020) and forecasted estimates (till 2035) for the global stem cell therapy market, distributed by source, origin, type and lineage of stem cell, route of administration, therapeutic area, end users and geographical regions, supported by conservative, base and optimistic scenario analyses.
Key Questions Answered in this Report
• What is the current, and expected future, size of the stem cell therapy market?
• What is the anticipated CAGR of the stem cell therapy market during the forecast period, till 2035?
• Which are the leading companies engaged in the development of stem cell therapies?
• Which source, origin and type of stem cell is likely to dominate the market during the forecast period?
• Which therapeutic area offers the most attractive growth opportunity for stem cell therapy developers?
• Which region is likely to lead the stem cell therapy market, and which region is expected to grow the fastest?
• What are the key drivers, restraints, opportunities and challenges shaping this market?
• What is the prevailing contract manufacturing landscape for stem cell therapy developers, and which KPIs matter most when selecting a manufacturing partner?
Reasons to Buy this Report
This report is designed to give distributors, channel partners, and investors a decisive analytical edge in a fast-consolidating market. Its core differentiators include:
• The report provides a comprehensive, top-down market analysis, offering detailed revenue projections for the overall market and its specific sub-segments, valuable to both established market leaders and emerging entrants.
• It offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities and challenges, empowering data-driven strategic decision-making.
• It aids businesses in identifying and validating future growth opportunities across therapeutic areas and geographies.
• It supports the identification of unmet patient and customer demand by mapping the needs, preferences and behavior of key stakeholder groups.
• It equips new entrants with the requisite market intelligence to design and execute successful go-to-market and commercialization strategies.
• It enables more effective communication with investors, partners and other stakeholders, supporting the development of stronger business relationships.
Additional Benefits
• Complementary PPT Insights Pack
• Complementary Excel Data Packs for all Analytical Modules in the Report
• 15% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older
目錄 Table of Contents
1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control
3. MARKET DYNAMICS
3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach
3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis
3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations
4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations
4.2.2.3. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market
4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross Border Dynamics
4.3. Conclusion
5. EXECUTIVE SUMMARY
6. INTRODUCTION
6.1. Chapter Overview
6.2. Overview of Stem Cell Therapies
6.2.1. Historical Evolution of Stem Cell Research
6.2.2. Classification of Stem Cells
6.2.2.1. Based on Source of Stem Cell
6.2.2.2. Based on Origin of Stem Cell
6.2.2.3. Based on Potency of Stem Cell
6.2.3. Administration of Stem Cell Therapies
6.2.4. Applications of Stem Cell Therapies
6.2.5. Challenges Associated with Development of Stem Cell Therapies
6.3. Regulatory Guidelines for Stem Cell Therapies
6.3.1. Current Scenario
6.3.2. Regulatory Guidelines in North America
6.3.3. Regulatory Guidelines in Europe
6.3.4. Regulatory Guidelines in Japan
6.4. Prevalent Trends Related to Stem Cell Therapies
6.4.1. Emerging Focus Areas
6.4.2. Key Historical Trends
6.4.3. Geographical Activity
6.5. Growth Drivers and Roadblocks
7. MARKET LANDSCAPE
7.1. Chapter Overview
7.2. Stem Cell Therapies: Marketed and Development Pipeline
7.2.1. Analysis by Phase of Development
7.2.2. Analysis by Source of Stem Cell
7.2.3. Analysis by Origin of Stem Cell
7.2.4. Analysis by Type of Stem Cell
7.2.5. Analysis by Lineage of Stem Cell
7.2.6. Analysis by Potency of Stem Cell
7.2.7. Analysis by Target Indication
7.2.8. Analysis by Therapeutic Area
7.2.9. Analysis by Route of Administration
7.3. Stem Cell Therapies: Additional Information
7.3.1. Information on Dosage and Commercial Rights
7.3.2. Information on Designations Awarded
7.4. Stem Cell Therapies: List of Technology Platforms
7.5. Stem Cell Therapies: List of Therapy Developers
7.5.1. Analysis by Year of Establishment
7.5.2. Analysis by Company Size
7.5.3. Analysis by Location of Headquarters
7.5.4. Analysis by Company Size and Location of Headquarters
7.5.5. Leading Drug Developers: Analysis by Number of Stem Cell Therapies
7.5.6. Leading Drug Developers: 4D Bubble Analysis based on Strength of Pipeline, Target Indication and Company Size
7.6. Heptagon Representation: Analysis by Phase of Development and Key Therapeutic Area
7.7. Grid Representation: Analysis by Phase of Development, Source of Stem Cell and Therapeutic Area
7.8. Tree Map Representation: Analysis by Therapeutic Area and Size of the Company
7.9. World Map Representation: Analysis of Regional Activity
8. COMPANY PROFILES
8.1. Chapter Overview
8.1.1. Anterogen
8.1.1.1. Company Overview
8.1.1.2. Product Portfolio
8.1.1.3. Recent Developments and Future Outlook
8.1.2. Athersys
8.1.3. CHA Biotech
8.1.4. Cytopeutics
8.1.5. Hope Biosciences
8.1.6. Mesoblast
8.1.7. Pluristem Therapeutics
8.1.8. Takeda Pharmaceutical
8.1.9. TICEBA
9. KEY THERAPEUTIC AREAS
9.1. Chapter Overview
9.2. Autoimmune / Inflammatory Disorders
9.2.1. Crohn’s Disease
9.2.1.1. Disease Description
9.2.1.2. Epidemiology
9.2.1.3. Current Treatment Options
9.2.1.4. Side Effects of Current Treatment Options
9.2.1.5. Stem Cell Therapies for Crohn’s Disease
9.2.2. Ulcerative Colitis
9.2.2.1. Disease Description
9.2.2.2. Epidemiology
9.2.2.3. Current Treatment Options
9.2.2.4. Side Effects of Current Treatment Options
9.2.2.5. Stem Cell Therapies for Ulcerative Colitis
9.3. Cardiovascular Disorders
9.3.1. Critical Limb Ischemia
9.3.1.1. Disease Description
9.3.1.2. Epidemiology
9.3.1.3. Current Treatment Options
9.3.1.3.1. Pharmacological Interventions
9.3.1.3.2. Endovascular Treatments
9.3.1.3.3. Surgical Interventions
9.3.1.4. Stem Cell Therapies for Critical Limb Ischemia
9.3.2. Heart Failure
9.3.2.1. Disease Description
9.3.2.2. Epidemiology
9.3.2.3. Current Treatment Options
9.3.2.3.1. Pharmacological Interventions
9.3.2.3.2. Therapeutic Devices
9.3.2.3.3. Surgical Interventions
9.3.2.4. Stem Cell Therapies for Heart Failure
9.3.3. Myocardial Infarction
9.3.3.1. Disease Description
9.3.3.2. Epidemiology
9.3.3.3. Current Treatment Options
9.3.3.3.1. Pharmacological Interventions
9.3.3.3.2. Surgical Interventions
9.3.3.4. Stem Cell Therapies for Myocardial Infarction
9.4. Dermatological Disorders
9.4.1. Acne Vulgaris
9.4.1.1. Disease Description
9.4.1.2. Epidemiology
9.4.1.3. Current Treatment Options
9.4.1.4. Side Effects of Current Treatment Options
9.4.1.5. Stem Cell Therapies for Acne Vulgaris
9.5. Metabolic Disorders
9.5.1. Diabetes
9.5.1.1. Disease Description
9.5.1.2. Associated Health Risks / Complications
9.5.1.3. Epidemiology
9.5.1.4. Disease Diagnosis
9.5.1.5. Current Treatment Options
9.5.1.5.1. Insulin Therapies
9.5.1.5.2. Non-Insulin Therapies
9.5.1.6. Side Effects of Current Treatment Options
9.5.1.7. Stem Cell Therapies for Diabetes
9.5.2. Non-alcoholic Steatohepatitis (NASH)
9.5.2.1. Disease Description
9.5.2.2. Epidemiology
9.5.2.3. Current Treatment Options
9.5.2.4. Stem Cell Therapies for NASH
9.6. Oncological Disorders
9.6.1. Bladder Cancer
9.6.1.1. Disease Description
9.6.1.2. Epidemiology
9.6.1.3. Current Treatment Options
9.6.1.4. Stem Cell Therapies for Bladder Cancer
9.6.2. Breast Cancer
9.6.2.1. Disease Description
9.6.2.2. Epidemiology
9.6.2.3. Current Treatment Options
9.6.2.4. Stem Cell Therapies for Breast Cancer
9.6.3. Colorectal Cancer
9.6.3.1. Disease Description
9.6.3.2. Epidemiology
9.6.3.3. Current Treatment Options
9.6.3.4. Side Effects of Current Treatment Options
9.6.3.5. Stem Cell Therapies for Colorectal Cancer
9.6.4. Kidney Cancer
9.6.4.1. Disease Description
9.6.4.2. Epidemiology
9.6.4.3. Current Treatment Options
9.6.4.4. Stem Cell Therapies for Kidney Cancer
9.6.5. Liver Cancer
9.6.5.1. Introduction
9.6.5.2. Epidemiology
9.6.5.3. Current Treatment Options
9.6.5.4. Stem Cell Therapies for Liver Cancer
9.6.6. Lung Cancer
9.6.6.1. Disease Description
9.6.6.2. Epidemiology
9.6.6.3. Current Treatment Options
9.6.6.4. Side Effects of Current Treatment Options
9.6.6.5. Stem Cell Therapies for Lung Cancer
9.6.7. Ovarian Cancer
9.6.7.1. Disease Description
9.6.7.2. Epidemiology
9.6.7.3. Current Treatment Options
9.6.7.4. Stem Cell Therapies for Ovarian Cancer
9.6.8. Pancreatic Cancer
9.6.8.1. Disease Description
9.6.8.2. Epidemiology
9.6.8.3. Current Treatment Options
9.6.8.4. Stem Cell Based Therapies for Pancreatic Cancer
9.7. Neurological Disorders
9.7.1. Alzheimer’s Disease
9.7.1.1. Disease Description
9.7.1.2. Epidemiology
9.7.1.3. Symptoms of the Disease
9.7.1.4. Causes of Alzheimer’s Disease
9.7.1.5. Stages of Alzheimer’s Disease
9.7.1.6. Current Treatment Options
9.7.1.7. Stem Cell Therapies for Alzheimer’s Disease
9.7.2. Parkinson’s Disease
9.7.2.1. Disease Description
9.7.2.2. Epidemiology
9.7.2.3. Current Treatment Options
9.7.2.3.1. Pharmacological Management of Parkinson’s Disease
9.7.2.3.2. Non-Pharmacological Management of Parkinson’s Disease
9.7.2.3.3. Management of Parkinson’s Disease Using Dietary Supplements
9.7.2.4. Stem Cell Therapies for Parkinson’s Disease
10. ASSESSMENT OF RELATIVE COMPETITION AND GROWTH
10.1. Chapter Overview
10.2. Assumptions and Methodology
10.3. Analysis of Relative Competition and Growth Opportunities
10.3.1. Established Therapeutic Areas in Emerging Regions
10.3.2. Established Therapeutic Areas in Established Regions
10.3.3. Emerging Therapeutic Areas in Emerging Regions
10.3.4. Emerging Therapeutic Areas in Established Regions
11. ACADEMIC GRANTS ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Stem Cell Therapies: Analysis of Grants Awarded by the National Institutes of Health (NIH)
11.3.1. Analysis by Year of Award
11.3.2. Analysis by Amount Awarded
11.3.3. Analysis by Administering Institute Center
11.3.4. Analysis by Funding Institute Center
11.3.5. Analysis by Support Period
11.3.6. Analysis by Funding Institute Center and Support Period
11.3.7. Most Popular NIH Spending Categorizations
11.3.8. Analysis by Funding Mechanism
11.3.9. Emerging Focus Areas
11.3.10. Analysis by Source of Stem Cell
11.3.11. Analysis by Origin of Stem Cell
11.3.12. Analysis by Type of Stem Cell
11.3.13. Analysis by Lineage of Stem Cell
11.3.14. Analysis by Potency of Stem Cell
11.3.15. Analysis by Therapeutic Area
11.3.16. Analysis by Type of Grant Application
11.3.17. Popular NIH Departments
11.3.18. Analysis by Study Section
11.3.19. Analysis by Types of Recipient Organizations
11.3.20. Popular Recipient Organizations
11.3.21. Analysis by Grant Mechanism
11.3.22. Prominent Program Officers
11.3.23. Regional Distribution of Recipient Organizations
11.4. Grant Attractiveness Analysis
12. CLINICAL TRIAL ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Stem Cell Therapies: Clinical Trial Analysis
12.3.1. Analysis by Trial Registration Year
12.3.2. Analysis by Trial Phase
12.3.3. Analysis by Number of Patients Enrolled by Trial Registration Year
12.3.4. Analysis by Study Design
12.3.5. Analysis by Trial Recruitment Status
12.3.6. Analysis by Sponsor / Collaborator
12.3.7. Leading Industry Sponsors: Based on Number of Registered Trials
12.3.8. Analysis by Trial Focus
12.3.9. Analysis by Type of Stem Cell
12.3.10. Analysis by Therapeutic Area
12.3.11. Analysis by Type of Stem Cell and Therapeutic Area
12.3.12. Geographical Analysis by Number of Clinical Trials
12.3.13. Geographical Analysis by Trial Recruitment Status
12.3.14. Geographical Analysis by Enrolled Patient Population
13. STEM CELL MANUFACTURING MARKET LANDSCAPE AND KPIs FOR EVALUATING CONTRACT SERVICES PARTNERS
13.1. Chapter Overview
13.2. Stem Cell Therapy Manufacturing
13.2.1. Need for Stem Cell Therapy Contract Manufacturing
13.2.2. Advantages of Outsourcing Stem Cell Therapy Manufacturing
13.2.3. Guidelines for Selecting a Contract Manufacturing Organization (CMO) Partner
13.2.4. Stem Cell Therapy CMOs: List of Industry Players
13.2.4.1. Analysis by Year of Establishment
13.2.4.2. Analysis by Company Size
13.2.4.3. Analysis by Scale of Stem Cell Manufacturing
13.2.4.4. Analysis by Location of Headquarters
13.2.4.5. Analysis by Location of Manufacturing Facilities
13.2.4.6. Analysis by Types of Services Offered
13.2.4.7. Analysis by Source and Origin of Stem Cell
13.2.5. Stem Cell Therapy CMOs: List of Non-industry Players
13.2.5.1. Analysis by Year of Establishment
13.2.5.2. Analysis by Scale of Stem Cell Manufacturing
13.2.5.3. Analysis by Location of Headquarters
13.2.5.4. Analysis by Location of Manufacturing Facilities
13.2.5.5. Analysis by Types of Services Offered
13.2.5.6. Analysis by Source and Origin Stem Cell
13.3. Stem Cell Therapy Manufacturing: KPI Analysis
13.3.1. KPI Definitions
13.3.1.1. Financial Indicators
13.3.1.1.1. Big Pharma Perspective
13.3.1.1.2. Contract Manufacturers’ Perspective
13.3.1.2. Process and Capability Indicators
13.3.1.2.1. Big Pharma Perspective
13.3.1.2.2. Contract Manufacturers’ Perspective
13.3.1.3. Market Reputation Indicators
13.3.1.3.1. Big Pharma Perspective
13.3.1.3.2. Contract Manufacturers’ Perspective
13.4. Concluding Remarks
14. STEM CELL THERAPY DEVELOPERS AND CMOs: OPPORTUNITY ASSESSMENT
14.1. Chapter Overview
14.2. Therapy Developers and CMOs in North America
14.2.1. Gap Analysis by Scale of Stem Cell Manufacturing
14.2.2. Gap Analysis by Source of Stem Cell
14.2.3. Gap Analysis by Origin of Stem Cell
14.3. Therapy Developers and CMOs in Europe
14.3.1. Gap Analysis by Scale of Stem Cell Manufacturing
14.3.2. Gap Analysis by Source of Stem Cell
14.3.3. Gap Analysis by Origin of Stem Cell
14.4. Therapy Developers and CMOs in Asia-Pacific and Rest of the World
14.4.1. Gap Analysis by Scale of Stem Cell Manufacturing
14.4.2. Gap Analysis by Source of Stem Cell
14.4.3. Gap Analysis by Origin of Stem Cell
14.5. Concluding Remarks
15. KEY COMMERCIALIZATION STRATEGIES
15.1. Chapter Overview
15.2. Successful Drug Launch Strategy: ROOTS Framework
15.3. Successful Drug Launch Strategy: Product Differentiation
15.4. Commonly Adopted Commercialization Strategies based on Stage of Product Development
15.5. Key Approved Stem Cell Therapies: Profiles
15.5.1. CARTISTEM®
15.5.2. HiQCell®
15.5.3. Prochymal®
15.5.4. Strimvelis®
15.6. Key Commercialization Strategies Adopted by Stem Cell Therapy Developers
15.6.1. Strategies Adopted before Therapy Approval
15.6.1.1. Participation in Global Events
15.6.1.2. Collaboration with Stakeholders and Pharmaceutical Firms
15.6.1.3. Seeking Approval for Multiple Target Indications
15.6.1.4. Seeking Special Therapy Designations and Other Credentials
15.6.1.5. Leveraging Uniqueness to Establish Competitive Edge
15.6.1.6. Anticipation of Likely Market Dynamics and Trends
15.6.1.7. Outsourcing Manufacturing Operations
15.6.2. Strategies Adopted Post Therapy Approval
15.6.2.1. Geographical Expansion
15.6.2.2. Participation in Global Events
15.6.2.3. Patient Assistance Programs
15.6.2.4. Miscellaneous Programs
15.7. Opportunities and Challenges with Unapproved Therapies
15.8. Concluding Remarks
16. GLOBAL STEM CELL THERAPY MARKET
16.1. Chapter Overview
16.2. Key Assumptions and Methodology
16.3. Stem Cell Therapy Market, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
16.3.1. Scenario Analysis
16.3.1.1. Conservative Scenario
16.3.1.2. Base Scenario
16.3.1.3. Optimistic Scenario
16.3.2. Key Market Segmentations
16.4. Data Triangulation and Validation
17. STEM CELL THERAPY MARKET, BY SOURCE OF STEM CELL
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Stem Cell Therapy Market: Distribution by Source of Stem Cell
17.3.1. Stem Cell Therapy Market for Allogeneic Therapies, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
17.3.2. Stem Cell Therapy Market for Autologous Therapies, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
17.4. Data Triangulation and Validation
18. STEM CELL THERAPY MARKET, BY ORIGIN OF STEM CELL
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Stem Cell Therapy Market: Distribution by Origin of Stem Cell
18.3.1. Stem Cell Therapy Market for Adult Stem Cells, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
18.3.2. Stem Cell Therapy Market for Embryonic Stem Cells, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
18.4. Data Triangulation and Validation
19. STEM CELL THERAPY MARKET, BY TYPE OF STEM CELL
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Stem Cell Therapy Market: Distribution by Type of Stem Cell
19.3.1. Stem Cell Therapy Market for Hematopoietic Stem Cells, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
19.3.2. Stem Cell Therapy Market for Mesenchymal Stem Cells, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
19.3.3. Stem Cell Therapy Market for Progenitor Cells, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
19.3.4. Stem Cell Therapy Market for Other Stem Cells, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
19.4. Data Triangulation and Validation
20. STEM CELL THERAPY MARKET, BY LINEAGE OF STEM CELL
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Stem Cell Therapy Market: Distribution by Lineage of Stem Cell
20.3.1. Stem Cell Therapy Market for Adipose Tissue Derived Stem Cells, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
20.3.2. Stem Cell Therapy Market for Bone Marrow Derived Stem Cells, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
20.3.3. Stem Cell Therapy Market for Cord Blood Derived Stem Cells, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
20.4. Data Triangulation and Validation
21. STEM CELL THERAPY MARKET, BY ROUTE OF ADMINISTRATION
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Stem Cell Therapy Market: Distribution by Route of Administration
21.3.1. Stem Cell Therapy Market for Intraarticular Therapies, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
21.3.2. Stem Cell Therapy Market for Intracoronary Therapies, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
21.3.3. Stem Cell Therapy Market for Intramuscular Therapies, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
21.3.4. Stem Cell Therapy Market for Intramyocardial Therapies, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
21.3.5. Stem Cell Therapy Market for Intrathecal Therapies, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
21.3.6. Stem Cell Therapy Market for Intravenous Therapies, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
21.3.7. Stem Cell Therapy Market for Surgical Implants, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
21.3.8. Stem Cell Therapy Market for Other Routes of Administration, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
21.4. Data Triangulation and Validation
22. STEM CELL THERAPY MARKET, BY THERAPEUTIC AREA
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Stem Cell Therapy Market: Distribution by Therapeutic Area
22.3.1. Stem Cell Therapy Market for Autoimmune / Inflammatory Disorders, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
22.3.2. Stem Cell Therapy Market for Cardiovascular Disorders, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
22.3.3. Stem Cell Therapy Market for Metabolic Disorders, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
22.3.4. Stem Cell Therapy Market for Musculoskeletal Disorders, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
22.3.5. Stem Cell Therapy Market for Oncological Disorders, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
22.3.6. Stem Cell Therapy Market for Neurological Disorders, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
22.3.7. Stem Cell Therapy Market for Ophthalmic Disorders, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
22.3.8. Stem Cell Therapy Market for Others, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
22.4. Data Triangulation and Validation
23. STEM CELL THERAPY MARKET, BY END USERS
23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Stem Cell Therapy Market: Distribution by End Users
23.3.1. Stem Cell Therapy Market for Ambulatory Surgery Centers, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
23.3.2. Stem Cell Therapy Market for Hospitals, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
23.3.3. Stem Cell Therapy Market for Specialty Clinics, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
23.4. Data Triangulation and Validation
24. STEM CELL THERAPY MARKET, BY GEOGRAPHICAL REGIONS
24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. Stem Cell Therapy Market: Distribution by Geographical Regions
24.3.1. Stem Cell Therapy Market in North America, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.3.2. Stem Cell Therapy Market in Europe, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.3.3. Stem Cell Therapy Market in Asia-Pacific, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.3.4. Stem Cell Therapy Market in Rest of the World, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.4. Market Dynamics Assessment
24.4.1. Market Movement Analysis
24.4.2. Penetration-Growth (P-G) Matrix
24.5. Data Triangulation and Validation
25. CONCLUDING INSIGHTS
26. EXECUTIVE INSIGHTS
26.1. Chapter Overview
26.2. Company A
26.2.1. Company Snapshot
26.2.2. Interview Transcript: Founder and Chief Executive Officer
26.3. Company B
26.3.1. Company Snapshot
26.3.2. Interview Transcript: Founder and Chief Executive Officer
26.4. Company C
26.4.1. Company Snapshot
26.4.2. Interview Transcript: Director and Chairman, Department of Cardiac Surgery
26.5. Company D
26.5.1. Company Snapshot
26.5.2. Interview Transcript: Director and Chief Operating Officer
26.6. Company E
26.6.1. Company Snapshot
26.6.2. Interview Transcript: Director of Business Development
26.7. Company F
26.7.1. Company Snapshot
26.7.2. Interview Transcript: Scientific & Medical Director
26.8. Company G
26.8.1. Company Snapshot
26.8.2. Interview Transcript: Co-Founder and Chief Scientist; Former Director, Business Development
26.9. Company H
26.9.1. Company Snapshot
26.9.2. Interview Transcript: Former President
26.10. Company I
26.10.1. Company Snapshot
26.10.2. Interview Transcript: Former Department Leader, Cell Therapy Innovation and Development
26.11. Company J
26.11.1. Company Snapshot
26.11.2. Interview Transcript: President and Chief Executive Officer
26.12. Company K
26.12.1. Company Snapshot
26.12.2. Interview Transcript: Chief Executive Officer and Co-founder
26.13. Company L
26.13.1. Company Snapshot
26.13.2. Interview Transcript: Chief Executive Officer and Co-founder
26.14. Company M
26.14.1. Company Snapshot
26.14.2. Interview Transcript: President and Co-founder
26.15. Company N
26.15.1. Company Snapshot
26.15.2. Interview Transcript: Chief Executive Officer
26.16. Company O
26.16.1. Company Snapshot
26.16.2. Interview Transcript: Chief Executive Officer
26.17. Company P
26.17.1. Company Snapshot
26.17.2. Interview Transcript: Founder and Chief Technology Officer
26.18. Company Q
26.18.1. Company Snapshot
26.18.2. Interview Transcript: Vice President of Cell Technology
26.19. Company R
26.19.1. Company Snapshot
26.19.2. Interview Transcript: Associate Director, Regulatory Affairs
26.20. Company S
26.20.1. Company Snapshot
26.20.2. Interview Transcript: Team Leader, Research and Development
27. APPENDIX I: TABULATED DATA
28. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
圖表清單 List of Tables & Figures
Table 6.1 Differences between Stem Cell Therapies and Other Biologics
Table 7.1 Stem Cell Therapies: Marketed and Development Pipeline
Table 7.2 Stem Cell Therapies Pipeline: Information on Target Indication, Therapeutic Area and Route of Administration
Table 7.3 Stem Cell Therapies Pipeline: Information on Dosage and Commercial Rights
Table 7.4 Stem Cell Therapies Pipeline: Information on Special Designations
Table 7.5 Stem Cell Therapies Pipeline: Information on Technology Platforms
Table 7.6 Stem Cell Therapies Pipeline: List of Therapy Developers
Table 8.1 List of Companies Profiles
Table 8.2 Anterogen: Company Profile
Table 8.3 Product Portfolio: Clinical-Stage Stem Cell Therapies
Table 8.4 Anterogen: Recent Developments and Future Outlook
Table 8.5 Athersys: Company Profile
Table 8.6 Product Portfolio: Clinical-Stage Stem Cell Therapies
Table 8.7 Athersys: Recent Developments and Future Outlook
Table 8.8 CHA Biotech: Company Profile
Table 8.9 Product Portfolio: Clinical-Stage Stem Cell Therapies
Table 8.10 CHA Biotech: Recent Developments and Future Outlook
Table 8.11 Cytopeutics: Company Profile
Table 8.12 Product Portfolio: Clinical-Stage Stem Cell Therapies
Table 8.13 Cytopeutics: Recent Developments and Future Outlook
Table 8.14 Hope Biosciences: Company Profile
Table 8.15 Product Portfolio: Clinical-Stage Stem Cell Therapies
Table 8.16 Hope Biosciences: Recent Developments and Future Outlook
Table 8.17 Mesoblast: Company Profile
Table 8.18 Product Portfolio: Clinical-Stage Stem Cell Therapies
Table 8.19 Mesoblast: Recent Developments and Future Outlook
Table 8.20 Pluristem Therapeutics: Company Profile
Table 8.21 Product Portfolio: Clinical-Stage Stem Cell Therapies
Table 8.22 Pluristem Therapeutics: Recent Developments and Future Outlook
Table 8.23 Takeda Pharmaceutical: Company Profile
Table 8.24 Product Portfolio: Clinical-Stage Stem Cell Therapies
Table 8.25 Takeda Pharmaceutical: Recent Developments and Future Outlook
Table 8.26 TICEBA: Company Profile
Table 8.27 Product Portfolio: Clinical-Stage Stem Cell Therapies
Table 8.28 TICEBA: Recent Developments and Future Outlook
Table 9.1 Crohn’s Disease: Current Treatment Options
Table 9.2 Crohn’s Disease: Side Effects of Current Treatment Options
Table 9.3 Crohn’s Disease: Stem Cell Therapeutics Pipeline
Table 9.4 Ulcerative Colitis: Current Treatment Options
Table 9.5 Ulcerative Colitis: Side Effects of Current Treatment Options
Table 9.6 Ulcerative Colitis: Stem Cell Therapeutics Pipeline
Table 9.7 Peripheral Arterial Diseases: List of Marketed Drugs
Table 9.8 Critical Limb Ischemia: Stem Cell Therapeutics Pipeline
Table 9.9 Heart Failure: List of Marketed Drugs
Table 9.10 Heart Failure: Stem Cell Therapeutics Pipeline
Table 9.11 Heart Failure: List of Marketed Drugs
Table 9.12 Myocardial Infarction: List of Marketed Drugs
Table 9.13 Myocardial Infarction: Stem Cell Therapeutics Pipeline
Table 9.14 Acne Vulgaris: Current Treatment Options
Table 9.15 Acne Vulgaris: Side Effects of Current Treatment Options
Table 9.16 Acne Vulgaris: Stem Cell Therapeutics Pipeline
Table 9.17 Diabetes: Current Treatment Options
Table 9.18 Diabetes: Side Effects of Current Treatment Options
Table 9.19 Diabetes: Stem Cell Therapeutics Pipeline
Table 9.20 Non-Alcoholic Steatohepatitis: Stem Cell Therapeutics Pipeline
Table 9.21 Bladder Cancer: List of Marketed Targeted Therapeutics
Table 9.22 Breast Cancer: List of Marketed Targeted Therapeutics
Table 9.23 Colorectal Cancer: Side Effects of Current Treatments
Table 9.24 Kidney Cancer: List of Marketed Targeted Therapeutics
Table 9.25 Liver Cancer: List of Marketed Targeted Therapeutics
Table 9.26 Lung Cancer: List of Marketed Targeted Therapeutics
Table 9.27 Lung Cancer: Side Effects of Current Treatments
Table 9.28 Ovarian Cancer: List of Marketed Targeted Therapeutics
Table 9.29 Pancreatic Cancer: List of Marketed Targeted Therapeutics
Table 9.30 Pancreatic Cancer: Stem Cell Therapeutics Pipeline
Table 9.31 Alzheimer’s Disease: Current Treatment Options
Table 9.32 Alzheimer’s Disease: Stem Cell Therapeutics Pipeline
Table 9.33 Parkinson’s Disease: Current Treatment Options
Table 9.34 Parkinson’s Disease: Stem Cell Therapeutics Pipeline
Table 11.1 Grant Analysis: List of Most Attractive Grants
Table 27.1 Stem Cell Therapies: Distribution by Phase of Development
Table 27.2 Stem Cell Therapies: Distribution by Source of Stem Cell
Table 27.3 Stem Cell Therapies: Distribution by Origin of Stem Cell
Table 27.4 Stem Cell Therapies: Distribution by Type of Stem Cell
Table 27.5 Stem Cell Therapies: Distribution by Lineage of Stem Cell
Table 27.6 Stem Cell Therapies: Distribution by Potency of Stem Cell
Table 27.7 Stem Cell Therapies: Distribution by Target Indication
Table 27.8 Stem Cell Therapies: Distribution by Therapeutic Area
Table 27.9 Stem Cell Therapies: Distribution by Route of Administration
Table 27.10 Stem Cell Therapy Developers: Distribution by Year of Establishment
Table 27.11 Stem Cell Therapy Developers: Distribution by Company Size
Table 27.12 Stem Cell Therapy Developers: Distribution by Location of Headquarters
Table 27.13 Stem Cell Therapy Developers: Distribution by Company Size and Location of Headquarters
Table 27.14 Leading Stem Cell Therapy Developers: Distribution by Number of Stem Cell Therapies
Table 27.15 Grant Analysis: Cumulative Trend by Year of Award, Since 2015
Table 27.16 Grant Analysis: Cumulative Trend by Amount Awarded, Since 2015 (USD Million)
Table 27.17 Grant Analysis: Distribution by Administering Institute Center
Table 27.18 Grant Analysis: Distribution by Funding Institute Center
Table 27.19 Grant Analysis: Distribution by Support Period
Table 27.20 Grant Analysis: Distribution by Funding Institute Center and Support Period
Table 27.21 Grant Analysis: Most Popular NIH Funding Categorizations
Table 27.22 Grant Analysis: Distribution by Funding Mechanism
Table 27.23 Grant Analysis: Emerging Focus Areas
Table 27.24 Grant Analysis: Distribution by Source of Stem Cell
Table 27.25 Grant Analysis: Distribution by Origin of Stem Cell
Table 27.26 Grant Analysis: Distribution by Type of Stem Cell
Table 27.27 Grant Analysis: Year-Wise Trend in Activity for Different Types of Stem Cells
Table 27.28 Grant Analysis: Year-Wise Trend in Amount Awarded for Different Types of Stem Cells (USD Million)
Table 27.29 Grant Analysis: Distribution by Lineage of Stem Cell
Table 27.30 Grant Analysis: Distribution by Potency of Stem Cell
Table 27.31 Grant Analysis: Distribution by Therapeutic Area
Table 27.32 Grant Analysis: Year-Wise Trend in Activity for Popular Therapeutic Areas
Table 27.33 Grant Analysis: Year-Wise Trend in Amount Awarded for Popular Therapeutic Areas (USD Million)
Table 27.34 Grant Analysis: Distribution by Type of Grant Application
Table 27.35 Grant Analysis: Popular NIH Departments
Table 27.36 Grant Analysis: Distribution by Study Section
Table 27.37 Grant Analysis: Types of Recipient Organizations
Table 27.38 Grant Analysis: Popular Recipient Organizations
Table 27.39 Grant Analysis: Distribution by Grant Mechanism
Table 27.40 Grant Analysis: Prominent Program Officers
Table 27.41 Grant Analysis: Regional Distribution of Recipient Organizations
Table 27.42 Grant Analysis: Categorizations based on Weighted Attractiveness Scores
Table 27.43 Grant Analysis: Multivariate Grant Attractiveness Analysis
Table 27.44 Clinical Trial Analysis: Scope and Methodology
Table 27.45 Clinical Trial Analysis: Distribution by Trial Status
Table 27.46 Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year, Pre-2021
Table 27.47 Clinical Trial Analysis: Distribution by Trial Phase
Table 27.48 Clinical Trial Analysis: Distribution by Number of Patients Enrolled by Trial Registration Year, Since 2021
Table 27.49 Clinical Trial Analysis: Distribution by Study Design
Table 27.50 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Recruitment Status
Table 27.51 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 27.52 Clinical Trial Analysis: Leading Industry Players
Table 27.53 Clinical Trial Analysis: Distribution by Focus Area
Table 27.54 Clinical Trial Analysis: Distribution by Type of Stem Cell
Table 27.55 Clinical Trial Analysis: Cumulative Distribution by Type of Stem Cell and Trial Registration Year
Table 27.56 Clinical Trial Analysis: Distribution by Therapeutic Area
Table 27.57 Clinical Trial Analysis: Year-Wise Trend in Activity for Popular Therapeutic Areas
Table 27.58 Clinical Trial Analysis: Distribution by Patient Enrollment and Therapeutic Area
Table 27.59 Clinical Trial Analysis: Year-Wise Trend in Patient Enrollment (in thousands) for Popular Therapeutic Areas
Table 27.60 Clinical Trial Analysis: Distribution by Type of Stem Cell and Therapeutic Area
Table 27.61 Clinical Trial Analysis: Geographical Distribution by Number of Trials
Table 27.62 Clinical Trial Analysis: Geographical Distribution by Trial Registration Year and Recruitment Status
Table 27.63 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Table 27.64 Key Steps Involved in the Manufacturing of Stem Cell Therapies
Table 27.65 Stem Cell Therapy CMOs (Industry): Distribution by Year of Establishment
Table 27.66 Stem Cell Therapy CMOs (Industry): Distribution by Company Size
Table 27.67 Stem Cell Therapy CMOs (Industry): Distribution by Scale of Manufacturing
Table 27.68 Stem Cell Therapy CMOs (Industry): Distribution by Location of Headquarters
Table 27.69 Stem Cell Therapy CMOs (Industry): Distribution by Location of Manufacturing Facilities
Table 27.70 Stem Cell Therapy CMOs (Industry): Distribution by Types of Services Offered
Table 27.71 Stem Cell Therapy CMOs (Industry): Distribution by Source of Stem Cell
Table 27.72 Stem Cell Therapy CMOs (Industry): Distribution by Origin of Stem Cell
Table 27.73 Stem Cell Therapy CMOs (Non-industry): Distribution by Year of Establishment
Table 27.74 Stem Cell Therapy CMOs (Non-industry): Distribution by Scale of Manufacturing
Table 27.75 Stem Cell Therapy CMOs (Non-industry): Distribution by Location of Headquarters
Table 27.76 Stem Cell Therapy CMOs (Non-industry): Distribution by Location of Manufacturing Facilities
Table 27.77 Stem Cell Therapy CMOs (Non-industry): Distribution by Types of Services Offered
Table 27.78 Stem Cell Therapy CMOs (Non-industry): Distribution by Source of Stem Cell
Table 27.79 Stem Cell Therapy CMOs (Non-industry): Distribution by Origin of Stem Cell
Table 27.80 Overall Stem Cell Therapies Market, till 2035 (USD Million)
Table 27.81 Stem Cell Therapies Market: Distribution by Source of Stem Cell
Table 27.82 Stem Cell Therapies Market for Allogeneic Therapies, till 2035 (USD Million)
Table 27.83 Stem Cell Therapies Market for Autologous Therapies, till 2035 (USD Million)
Table 27.84 Stem Cell Therapies Market: Distribution by Origin of Stem Cell
Table 27.85 Stem Cell Therapies Market for Adult Stem Cells, till 2035 (USD Million)
Table 27.86 Stem Cell Therapies Market for Embryonic Stem Cells, till 2035 (USD Million)
Table 27.87 Stem Cell Therapies Market: Distribution by Type of Stem Cell
Table 27.88 Stem Cell Therapies Market for Hematopoietic Stem Cells, till 2035 (USD Million)
Table 27.89 Stem Cell Therapies Market for Mesenchymal Stem Cells, till 2035 (USD Million)
Table 27.90 Stem Cell Therapies Market for Progenitor Cells, till 2035 (USD Million)
Table 27.91 Stem Cell Therapies Market for Others, till 2035 (USD Million)
Table 27.92 Stem Cell Therapies Market: Distribution by Lineage of Stem Cell
Table 27.93 Stem Cell Therapies Market for Adipose Tissue Derived Stem Cells, till 2035 (USD Million)
Table 27.94 Stem Cell Therapies Market for Bone Marrow Derived Stem Cells, till 2035 (USD Million)
Table 27.95 Stem Cell Therapies Market for Cord Blood Derived Stem Cells, till 2035 (USD Million)
Table 27.96 Stem Cell Therapies Market: Distribution by Route of Administration
Table 27.97 Stem Cell Therapies Market for Intraarticular Therapies, till 2035 (USD Million)
Table 27.98 Stem Cell Therapies Market for Intracoronary Therapies, till 2035 (USD Million)
Table 27.99 Stem Cell Therapies Market for Intramuscular Therapies, till 2035 (USD Million)
Table 27.100 Stem Cell Therapies Market for Intramyocardial Therapies, till 2035 (USD Million)
Table 27.101 Stem Cell Therapies Market for Intrathecal Therapies, till 2035 (USD Million)
Table 27.102 Stem Cell Therapies Market for Intravenous Therapies, till 2035 (USD Million)
Table 27.103 Stem Cell Therapies Market for Surgical Implants, till 2035 (USD Million)
Table 27.104 Stem Cell Therapies Market for Other Route of Administration, till 2035 (USD Million)
Table 27.105 Stem Cell Therapies Market: Distribution by Therapeutic Area
Table 27.106 Stem Cell Therapies Market for Autoimmune / Inflammatory Disorders, till 2035 (USD Million)
Table 27.107 Stem Cell Therapies Market for Cardiovascular Disorders, till 2035 (USD Million)
Table 27.108 Stem Cell Therapies Market for Metabolic Disorders, till 2035 (USD Million)
Table 27.109 Stem Cell Therapies Market for Musculoskeletal Disorders, till 2035 (USD Million)
Table 27.110 Stem Cell Therapies Market for Neurological Disorders, till 2035 (USD Million)
Table 27.111 Stem Cell Therapies Market for Oncological Disorders, till 2035 (USD Million)
Table 27.112 Stem Cell Therapies Market for Ophthalmic Disorders, till 2035 (USD Million)
Table 27.113 Stem Cell Therapies Market for Others, till 2035 (USD Million)
Table 27.114 Stem Cell Therapies Market: Distribution by End Users
Table 27.115 Stem Cell Therapies Market for Ambulatory Surgery Centers, till 2035 (USD Million)
Table 27.116 Stem Cell Therapies Market for Hospitals, till 2035 (USD Million)
Table 27.117 Stem Cell Therapies Market for Specialty Clinics, till 2035 (USD Million)
Table 27.118 Stem Cell Therapies Market: Distribution by Key Geographical Regions
Table 27.119 Stem Cell Therapies Market in North America, till 2035 (USD Million)
Table 27.120 Stem Cell Therapies Market in Europe, till 2035 (USD Million)
Table 27.121 Stem Cell Therapies Market in Asia-Pacific, till 2035 (USD Million)
Table 27.122 Stem Cell Therapies Market in Rest of the World, till 2035 (USD Million)
Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Data Sources for Secondary Research
Figure 2.3 Research Methodology: Robust Quality Control
Figure 3.1 Market Dynamics: Forecast Methodology
Figure 3.2 Market Dynamics: Market Assessment Framework
Figure 4.1 Lessons Learnt from Past Recessions
Figure 5.1 Executive Summary: Overall Market Landscape
Figure 5.2 Executive Summary: Market Trends
Figure 5.3 Executive Summary: Market Forecast and Opportunity Analysis
Figure 6.1 Cellular Lineages Used for the Isolation of Stem Cells
Figure 6.2 Steps Involved in the Development and Administration of Stem Cell Therapies
Figure 6.3 Classification of Stem Cells
Figure 6.4 Classification based on Source of Stem Cell
Figure 6.5 Differences between Allogeneic and Autologous Stem Cell Therapies
Figure 6.6 Classification based on Origin of Stem Cell
Figure 6.7 Classification based on Potency of Stem Cell
Figure 6.8 Key Application Areas for Stem Cell Therapies
Figure 6.9 Emerging Focus Areas: Google News
Figure 6.10 Historical Timeline: Analysis of Google Trends
Figure 6.11 Geographical Activity: Analysis of Google Trends
Figure 6.12 Stem Cell Therapies: Key Growth Drivers and Roadblocks
Figure 7.1 Stem Cell Therapies: Distribution by Phase of Development
Figure 7.2 Stem Cell Therapies: Distribution by Source of Stem Cell
Figure 7.3 Stem Cell Therapies: Distribution by Origin of Stem Cell
Figure 7.4 Stem Cell Therapies: Distribution by Type of Stem Cell
Figure 7.5 Stem Cell Therapies: Distribution by Lineage of Stem Cell
Figure 7.6 Stem Cell Therapies: Distribution by Potency of Stem Cell
Figure 7.7 Stem Cell Therapies: Distribution by Target Indication
Figure 7.8 Stem Cell Therapies: Distribution by Therapeutic Area
Figure 7.9 Stem Cell Therapies: Distribution by Route of Administration
Figure 7.10 Stem Cell Therapy Developers: Distribution by Year of Establishment
Figure 7.11 Stem Cell Therapy Developers: Distribution by Company Size
Figure 7.12 Stem Cell Therapy Developers: Distribution by Location of Headquarters
Figure 7.13 Stem Cell Therapy Developers: Distribution by Company Size and Location of Headquarters
Figure 7.14 Leading Stem Cell Therapy Developers: Distribution by Number of Stem Cell Therapies
Figure 7.15 Leading Stem Cell Therapy Developers: 4D Bubble Analysis based on Strength of Pipeline, Number of Therapies, Target Indication and Company Size
Figure 7.16 Heptagon Representation: Distribution by Phase of Development and Key Therapeutic Area
Figure 7.17 Grid Representation: Distribution by Phase of Development, Source of Stem Cell and Therapeutic Area
Figure 7.18 Tree Map Representation: Distribution by Therapeutic Area and Size of the Company
Figure 7.19 World Map Representation: Regional Activity
Figure 9.1 Critical Limb Ischemia: Risk Factors
Figure 9.2 Critical Limb Ischemia: Symptoms
Figure 9.3 Heart Failure: Types
Figure 9.4 Heart Failure: Risk Factors
Figure 9.5 Heart Failure: Symptoms
Figure 9.6 Myocardial Infarction: Risk Factors
Figure 9.7 Myocardial Infarction: Symptoms
Figure 9.8 Diabetes: Diagnostic Limits for Plasma Glucose Levels
Figure 9.9 Diabetes: Non-Insulin Therapies
Figure 9.10 Bladder Cancer: Global Epidemiological Distribution
Figure 9.11 Breast Cancer: Global Epidemiological Distribution
Figure 9.12 Kidney Cancer: Global Epidemiological Distribution
Figure 9.13 Liver Cancer: Global Epidemiological Distribution
Figure 9.14 Lung Cancer: Global Epidemiological Distribution
Figure 9.15 Ovarian Cancer: Global Epidemiological Distribution
Figure 9.16 Pancreatic Cancer: Global Epidemiological Distribution
Figure 9.17 Dementia: Global Epidemiological Distribution
Figure 9.18 Alzheimer’s Disease: Signs and Symptoms
Figure 9.19 Alzheimer’s Disease: Normal Brain versus Diseased Brain
Figure 9.20 Alzheimer’s Disease: Phases of Disease Progression
Figure 9.21 Parkinson’s Disease: Gender-wise Incidence Rates
Figure 9.22 Parkinson’s Disease: Non-Pharmacological Treatment Options
Figure 9.23 Parkinson’s Disease: Surgical Interventions
Figure 9.24 Parkinson’s Disease: Dietary Supplements
Figure 10.1 Relative Competition and Growth Opportunities Related to Stem Cell Therapies: Analytical Output
Figure 10.2 Relative Competition and Growth Opportunities Related to Established Therapeutic Areas in Emerging Regions
Figure 10.3 Relative Competition and Growth Opportunities Related to Established Therapeutic Areas in Established Regions
Figure 10.4 Relative Competition and Growth Opportunities Related to Emerging Therapeutic Areas in Emerging Regions
Figure 10.5 Relative Competition and Growth Opportunities Related to Emerging Therapeutic Areas in Established Regions
Figure 11.1 Grant Analysis: Cumulative Trend by Year of Award, Since 2015
Figure 11.2 Grant Analysis: Cumulative Trend by Amount Awarded, Since 2015 (USD Million)
Figure 11.3 Grant Analysis: Distribution by Administering Institute Center
Figure 11.4 Grant Analysis: Distribution by Funding Institute Center
Figure 11.5 Grant Analysis: Distribution by Support Period
Figure 11.6 Grant Analysis: Distribution by Funding Institute Center and Support Period
Figure 11.7 Grant Analysis: Most Popular NIH Funding Categorizations
Figure 11.8 Grant Analysis: Distribution by Funding Mechanism
Figure 11.9 Grant Analysis: Emerging Focus Areas
Figure 11.10 Grant Analysis: Distribution by Source of Stem Cell
Figure 11.11 Grant Analysis: Distribution by Origin of Stem Cell
Figure 11.12 Grant Analysis: Distribution by Type of Stem Cell
Figure 11.13 Grant Analysis: Year-Wise Trend in Activity for Different Types of Stem Cells
Figure 11.14 Grant Analysis: Year-Wise Trend in Amount Awarded for Different Types of Stem Cells (USD Million)
Figure 11.15 Grant Analysis: Distribution by Lineage of Stem Cell
Figure 11.16 Grant Analysis: Distribution by Potency of Stem Cell
Figure 11.17 Grant Analysis: Distribution by Therapeutic Area
Figure 11.18 Grant Analysis: Year-Wise Trend in Activity for Popular Therapeutic Areas
Figure 11.19 Grant Analysis: Year-Wise Trend in Amount Awarded for Popular Therapeutic Areas (USD Million)
Figure 11.20 Grant Analysis: Distribution by Type of Grant Application
Figure 11.21 Grant Analysis: Popular NIH Departments
Figure 11.22 Grant Analysis: Distribution by Study Section
Figure 11.23 Grant Analysis: Types of Recipient Organizations
Figure 11.24 Grant Analysis: Popular Recipient Organizations
Figure 11.25 Grant Analysis: Distribution by Grant Mechanism
Figure 11.26 Grant Analysis: Prominent Program Officers
Figure 11.27 Grant Analysis: Regional Distribution of Recipient Organizations
Figure 11.28 Grant Analysis: Categorizations based on Weighted Attractiveness Scores
Figure 11.29 Grant Analysis: Multivariate Grant Attractiveness Analysis
Figure 12.1 Clinical Trial Analysis: Scope and Methodology
Figure 12.2 Clinical Trial Analysis: Distribution by Trial Status
Figure 12.3 Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year, Pre-2021
Figure 12.4 Clinical Trial Analysis: Distribution by Trial Phase
Figure 12.5 Clinical Trial Analysis: Distribution by Number of Patients Enrolled by Trial Registration Year, Since 2021
Figure 12.6 Clinical Trial Analysis: Distribution by Study Design
Figure 12.7 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Recruitment Status
Figure 12.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 12.9 Clinical Trial Analysis: Leading Industry Players
Figure 12.10 Clinical Trial Analysis: Distribution by Focus Area
Figure 12.11 Clinical Trial Analysis: Distribution by Type of Stem Cell
Figure 12.12 Clinical Trial Analysis: Cumulative Distribution by Type of Stem Cell and Trial Registration Year
Figure 12.13 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 12.14 Clinical Trial Analysis: Year-Wise Trend in Activity for Popular Therapeutic Areas
Figure 12.15 Clinical Trial Analysis: Distribution by Patient Enrollment and Therapeutic Area
Figure 12.16 Clinical Trial Analysis: Year-Wise Trend in Patient Enrollment (in thousands) for Popular Therapeutic Areas
Figure 12.17 Clinical Trial Analysis: Distribution by Type of Stem Cell and Therapeutic Area
Figure 12.18 Clinical Trial Analysis: Geographical Distribution by Number of Trials
Figure 12.19 Clinical Trial Analysis: Geographical Distribution by Trial Registration Year and Recruitment Status
Figure 12.20 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Figure 13.1 Key Steps Involved in the Manufacturing of Stem Cell Therapies
Figure 13.2 Stem Cell Therapy CMOs (Industry): Distribution by Year of Establishment
Figure 13.3 Stem Cell Therapy CMOs (Industry): Distribution by Company Size
Figure 13.4 Stem Cell Therapy CMOs (Industry): Distribution by Scale of Manufacturing
Figure 13.5 Stem Cell Therapy CMOs (Industry): Distribution by Location of Headquarters
Figure 13.6 Stem Cell Therapy CMOs (Industry): Distribution by Location of Manufacturing Facilities
Figure 13.7 Stem Cell Therapy CMOs (Industry): Distribution by Types of Services Offered
Figure 13.8 Stem Cell Therapy CMOs (Industry): Distribution by Source of Stem Cell
Figure 13.9 Stem Cell Therapy CMOs (Industry): Distribution by Origin of Stem Cell
Figure 13.10 Stem Cell Therapy CMOs (Non-industry): Distribution by Year of Establishment
Figure 13.11 Stem Cell Therapy CMOs (Non-industry): Distribution by Scale of Manufacturing
Figure 13.12 Stem Cell Therapy CMOs (Non-industry): Distribution by Location of Headquarters
Figure 13.13 Stem Cell Therapy CMOs (Non-industry): Distribution by Location of Manufacturing Facilities
Figure 13.14 Stem Cell Therapy CMOs (Non-industry): Distribution by Types of Services Offered
Figure 13.15 Stem Cell Therapy CMOs (Non-industry): Distribution by Source of Stem Cell
Figure 13.16 Stem Cell Therapy CMOs (Non-industry): Distribution by Origin of Stem Cell
Figure 13.17 Financial Indicators: Comparative Analysis of KPIs Considered by Big Pharma Companies
Figure 13.18 Financial Indicators: Big Pharma Perspective
Figure 13.19 Financial Indicators: Contract Manufacturers’ Perspective
Figure 13.20 Process / Capability Indicators: Big Pharma Perspective
Figure 13.21 Process / Capability Indicators: Contract Manufacturers’ Perspective
Figure 13.22 Market Reputation Indicators: Comparative Analysis of KPIs of Big Pharma Companies
Figure 13.23 Market Reputation Indicators: Big Pharma Perspective
Figure 13.24 Market Reputation Indicators: Contract Manufacturers’ Perspective
Figure 14.1 Opportunity Assessment in North America: Gap Analysis by Scale of Stem Cell Manufacturing
Figure 14.2 Opportunity Assessment in North America: Gap Analysis by Source of Stem Cell
Figure 14.3 Opportunity Assessment in North America: Gap Analysis by Origin of Stem Cell
Figure 14.4 Opportunity Assessment in Europe: Gap Analysis by Scale of Stem Cell Manufacturing
Figure 14.5 Opportunity Assessment in Europe: Gap Analysis by Source of Stem Cell
Figure 14.6 Opportunity Assessment in Europe: Gap Analysis by Origin of Stem Cell
Figure 14.7 Opportunity Assessment in Asia-Pacific and Rest of the World: Gap Analysis by Scale of Stem Cell Manufacturing
Figure 14.8 Opportunity Assessment in Asia-Pacific and Rest of the World: Gap Analysis by Source of Stem Cell
Figure 14.9 Opportunity Assessment in Asia-Pacific and Rest of the World: Gap Analysis by Origin of Stem Cell
Figure 14.10 Stem Cell Therapy Developers and CMOs: Mapping Regional Presence
Figure 14.11 Stem Cell Therapy Developers and CMOs: Mapping Capabilities
Figure 15.1 Successful Drug Launch Strategy: ROOTS Framework
Figure 15.2 Commonly Adopted Commercialization Strategies based on Development Stage of the Product
Figure 15.3 Harvey Ball Analysis: Commercialization Strategies Adopted by Companies Focused on Stem Cell Therapies
Figure 15.4 Approved Stem Cell Therapies: Historical Timeline of Geographical Expansion
Figure 16.1 Overall Stem Cell Therapies Market, till 2035 (USD Million)
Figure 17.1 Stem Cell Therapies Market: Distribution by Source of Stem Cell
Figure 17.2 Stem Cell Therapies Market for Allogeneic Therapies, till 2035 (USD Million)
Figure 17.3 Stem Cell Therapies Market for Autologous Therapies, till 2035 (USD Million)
Figure 18.1 Stem Cell Therapies Market: Distribution by Origin of Stem Cell
Figure 18.2 Stem Cell Therapies Market for Adult Stem Cells, till 2035 (USD Million)
Figure 18.3 Stem Cell Therapies Market for Embryonic Stem Cells, till 2035 (USD Million)
Figure 19.1 Stem Cell Therapies Market: Distribution by Type of Stem Cell
Figure 19.2 Stem Cell Therapies Market for Hematopoietic Stem Cells, till 2035 (USD Million)
Figure 19.3 Stem Cell Therapies Market for Mesenchymal Stem Cells, till 2035 (USD Million)
Figure 19.4 Stem Cell Therapies Market for Progenitor Cells, till 2035 (USD Million)
Figure 19.5 Stem Cell Therapies Market for Others, till 2035 (USD Million)
Figure 20.1 Stem Cell Therapies Market: Distribution by Lineage of Stem Cell
Figure 20.2 Stem Cell Therapies Market for Adipose Tissue Derived Stem Cells, till 2035 (USD Million)
Figure 20.3 Stem Cell Therapies Market for Bone Marrow Derived Stem Cells, till 2035 (USD Million)
Figure 20.4 Stem Cell Therapies Market for Cord Blood Derived Stem Cells, till 2035 (USD Million)
Figure 21.1 Stem Cell Therapies Market: Distribution by Route of Administration
Figure 21.2 Stem Cell Therapies Market for Intraarticular Therapies, till 2035 (USD Million)
Figure 21.3 Stem Cell Therapies Market for Intracoronary Therapies, till 2035 (USD Million)
Figure 21.4 Stem Cell Therapies Market for Intramuscular Therapies, till 2035 (USD Million)
Figure 21.5 Stem Cell Therapies Market for Intramyocardial Therapies, till 2035 (USD Million)
Figure 21.6 Stem Cell Therapies Market for Intrathecal Therapies, till 2035 (USD Million)
Figure 21.7 Stem Cell Therapies Market for Intravenous Therapies, till 2035 (USD Million)
Figure 21.8 Stem Cell Therapies Market for Surgical Implants, till 2035 (USD Million)
Figure 21.9 Stem Cell Therapies Market for Other Route of Administration, till 2035 (USD Million)
Figure 22.1 Stem Cell Therapies Market: Distribution by Therapeutic Area
Figure 22.2 Stem Cell Therapies Market for Autoimmune / Inflammatory Disorders, till 2035 (USD Million)
Figure 22.3 Stem Cell Therapies Market for Cardiovascular Disorders, till 2035 (USD Million)
Figure 22.4 Stem Cell Therapies Market for Metabolic Disorders, till 2035 (USD Million)
Figure 22.5 Stem Cell Therapies Market for Musculoskeletal Disorders, till 2035 (USD Million)
Figure 22.6 Stem Cell Therapies Market for Neurological Disorders, till 2035 (USD Million)
Figure 22.7 Stem Cell Therapies Market for Oncological Disorders, till 2035 (USD Million)
Figure 22.8 Stem Cell Therapies Market for Ophthalmic Disorders, till 2035 (USD Million)
Figure 22.9 Stem Cell Therapies Market for Others, till 2035 (USD Million)
Figure 23.1 Stem Cell Therapies Market: Distribution by End Users
Figure 23.2 Stem Cell Therapies Market for Ambulatory Surgery Centers, till 2035 (USD Million)
Figure 23.3 Stem Cell Therapies Market for Hospitals, till 2035 (USD Million)
Figure 23.4 Stem Cell Therapies Market for Specialty Clinics, till 2035 (USD Million)
Figure 24.1 Stem Cell Therapies Market: Distribution by Key Geographical Regions
Figure 24.2 Stem Cell Therapies Market in North America, till 2035 (USD Million)
Figure 24.3 Stem Cell Therapies Market in Europe, till 2035 (USD Million)
Figure 24.4 Stem Cell Therapies Market in Asia-Pacific, till 2035 (USD Million)
Figure 24.5 Stem Cell Therapies Market in Rest of the World, till 2035 (USD Million)
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Roots Analysis 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們